Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: SRPT

Sarepta Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for SRPT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.90

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 18:45 UTC.

What Sarepta Therapeutics, Inc. does

The company operates in the pharmaceutical industry and faces significant regulatory uncertainty from potential healthcare reform at federal and state levels, including possible price controls, reimbursement restrictions, and changes to drug importation laws. The company's products depend on market adoption by patients, healthcare providers, and insurance payors, which can be affected by clinical efficacy demonstrations, reimbursement availability, and safety considerations.

Summarized from Sarepta Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.90
Debt/equity0.55

Revenue, margins & earnings

FY2021: net loss $419M on revenue $702M$702MFY2021FY2022: net loss $703M on revenue $933M$933MFY2022FY2023: net loss $536M on revenue $1.24B$1.24BFY2023FY2024 Revenue: $1.90B — margin split not shown (non-operating gains)$1.90BFY2024FY2025: net loss $713M on revenue $2.20B$2.20BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-08
  • 2026-09-08Chief Operating OfficerTax withholding-24,799$551.0K
  • 2026-09-08President, R&D and Tech OpsTax withholding-21,423$476.0K
  • 2026-09-08Chief Financial OfficerTax withholding-13,272$294.9K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Sarepta Therapeutics, Inc. do?

The company operates in the pharmaceutical industry and faces significant regulatory uncertainty from potential healthcare reform at federal and state levels, including possible price controls, reimbursement restrictions, and changes to drug importation laws.

When did SRPT last file with the SEC?

Sarepta Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-09-23. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 18:45 UTC. This page is also available as JSON at /api/data?ticker=SRPT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for SRPT and 5,000+ tickers.

Create a free account — keep SRPT
For your agent
GET /api/data?ticker=SRPT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt